Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2023-07-21 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Correction: Ipsen fait le point sur la demande d’autorisation de mise sur le marché européen de Bylvay® pour traiter le prurit cholestatique chez les patients atteints du syndrome d''Alagille
Regulatory Filings Classification · 1% confidence The document is a press release dated July 21, 2023, detailing regulatory updates regarding the drug Bylvay® in Europe (positive CHMP opinion for Alagille Syndrome, negative COMP opinion on orphan status maintenance) and referencing US FDA approval. It discusses clinical trial data (ASSERT study) and provides company background and contact information. This format—a formal announcement of significant business/regulatory developments, often summarizing key financial or operational milestones—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses heavily on clinical trial results and regulatory decisions impacting a key product, it aligns closely with the content typically found in an Earnings Release, which often includes operational highlights alongside financial summaries (though financials are sparse here, the structure is that of a major corporate update). However, given the specific focus on regulatory opinions (CHMP/COMP) and clinical trial outcomes rather than a comprehensive quarterly financial review (which would be an IR), and lacking any explicit mention of 'quarterly results' or 'financial performance' summary typical of an ER, it fits best as a significant, non-standard regulatory announcement. Since it is a detailed announcement of specific corporate/regulatory events rather than a short notice of a report being available (RPA), and it doesn't fit the other specific categories (like 10-K, IR, CT), the most appropriate classification is the general Regulatory Filings category (RNS), as it is a formal communication of material information to the market.
2023-07-21 French
Ipsen fait le point sur la demande d’autorisation de mise sur le marché européen de Bylvay® pour traiter le prurit cholestatique chez les patients atteints du syndrome d''Alagille
Regulatory Filings Classification · 1% confidence The document is a press release dated July 21, 2023, detailing regulatory updates regarding the drug Bylvay® in Europe (positive CHMP opinion for Alagille Syndrome, negative COMP opinion on orphan status maintenance) and referencing US FDA approval. It discusses clinical trial data (ASSERT study) and provides company background and contact information. This format—a formal announcement of significant business/regulatory developments, often summarizing key financial or operational milestones—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses heavily on clinical trial results and regulatory decisions impacting a key product, it aligns closely with the content typically found in an Earnings Release, which often includes operational highlights alongside financial summaries (though financials are sparse here, the structure is that of a major corporate update). However, given the specific focus on regulatory opinions (CHMP/COMP) and clinical trial outcomes rather than a comprehensive quarterly financial review (which would be an IR), and lacking any explicit mention of 'quarterly results' or 'financial performance' summary typical of an ER, it fits best as a significant, non-standard regulatory announcement. Since it is a detailed announcement of specific corporate/regulatory events rather than a short notice of a report being available (RPA), and it doesn't fit the other specific categories (like 10-K, IR, CT), the most appropriate classification is the general Regulatory Filings category (RNS), as it is a formal communication of material information to the market.
2023-07-21 French
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Regulatory Filings Classification · 1% confidence The document is a press release dated July 21, 2023, providing an update on the Marketing Authorization Application (MAA) for the drug Bylvay® in the E.U., specifically detailing positive and negative opinions from EMA committees (CHMP and COMP) regarding a new indication (Alagille syndrome). Key characteristics: 1. It announces regulatory/clinical developments (CHMP positive opinion, COMP negative opinion, appeal plans). 2. It includes detailed clinical trial data (ASSERT Phase III) and safety information. 3. It is a comprehensive update on a specific drug's regulatory pathway, not just a brief announcement of a report's availability. 4. It is too detailed and comprehensive to be a simple Earnings Release (ER) or a Report Publication Announcement (RPA). 5. It is not a full Annual Report (10-K) or a standard Interim Report (IR), as it focuses on a specific drug regulatory event rather than comprehensive financial statements for a period. This type of detailed, periodic update concerning drug development, regulatory milestones, and clinical data, often released outside of standard quarterly/annual financial reporting cycles, fits best under the general category of 'Regulatory Filings' (RNS) or potentially 'Legal Proceedings Report' (LTR) if the focus was purely on litigation, but here it's about regulatory decisions. However, given the options, this is a specific corporate announcement regarding regulatory progress and clinical data, which often falls into the general 'Regulatory Filings' category when a more specific category like 'LTR' (Legal) or 'ER' (Earnings) doesn't apply. Since it is a major corporate announcement regarding regulatory status, and not a general financial report, RNS is the most appropriate fallback for a specific, non-financial regulatory update that isn't a legal proceeding or management change. Revisiting definitions: It is not a CT, DIV, DIRS, MANG, NAV, etc. It is a detailed announcement about regulatory progress. While it contains clinical data, it is structured as a press release announcing regulatory outcomes. Given the lack of a specific 'Regulatory Update' category beyond RNS, and its focus on regulatory opinions rather than financial results (ER/IR) or governance (CGR), RNS is the best fit as a general regulatory announcement.
2023-07-21 English
Ipsen annonce la décision de la Commission européenne (CE) sur le palovarotène pour le traitement de la fibrodysplasie ossifiante progressive (FOP)
Legal Proceedings Report Classification · 1% confidence The document is a press release from Ipsen dated July 19, 2023, announcing a regulatory decision by the European Commission (CE) regarding the marketing authorization for the drug palovarotene for FOP. This announcement details the outcome of a regulatory review process (following a negative CHMP opinion) and discusses future regulatory steps in other countries. This type of communication, which reports on specific regulatory outcomes, clinical trial data context, and future regulatory strategy, is characteristic of a general corporate announcement related to drug development and regulatory affairs. Since it is not a full Annual Report (10-K), a quarterly report (IR), an earnings release (ER), or a specific shareholder vote result (DVA), it fits best under the general category for regulatory or corporate news that doesn't fit a more specific financial or governance code. Given the focus on a regulatory decision and the nature of the announcement (a press release detailing a specific event), it is most appropriately classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory Update, but RNS serves as the best fit for non-standard, significant corporate news releases that aren't strictly financial reporting or management changes. It is not an announcement of a report publication (RPA) because it *is* the substantive announcement itself, not just a notice that a report is available.
2023-07-19 French
Ipsen announces European Commission decision on palovarotene for the treatment of FOP
Regulatory Filings Classification · 1% confidence The document is a press release titled "Ipsen announces European Commission decision on palovarotene for the treatment of FOP." It details a specific regulatory outcome (negative marketing authorization decision) for a drug candidate. This type of announcement, focusing on a key regulatory event, clinical trial results, and business updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about a drug development milestone (regulatory decision) rather than a comprehensive financial report (10-K, IR) or a general regulatory filing fallback (RNS), it aligns best with the 'Earnings Release' (ER) category, which often includes significant operational and regulatory news alongside or instead of pure financial figures, especially in the biotech/pharma sector. Given the length and content structure (headline announcement, key takeaways, executive quotes, background on the drug/trial), it functions as a major corporate update, similar to how ERs are used for significant news outside of quarterly reporting periods, or as a standalone material event disclosure. However, since it is not explicitly a quarterly/periodical financial result announcement, and it is a specific regulatory update, the most appropriate general category for material, non-financial-report announcements is often RNS, but ER is used for major operational news. Given the focus on a major regulatory decision impacting the business, and the structure resembling a typical press release for material news, I will classify it as an Earnings Release (ER) as it conveys significant operational/pipeline news, which often accompanies or substitutes for ERs in this industry. If RNS were chosen, it would be the fallback. ER is chosen because it is a major, time-sensitive announcement of business progress/setback.
2023-07-19 English
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023
Transaction in Own Shares Classification · 1% confidence The document text consists of detailed tables reporting transactions in own shares ('Statement of transactions in own shares from July 10, 2023 to July 14, 2023'). The data includes issuer name, transaction dates, financial instrument codes, volume, price, and market codes. This structure is characteristic of regulatory filings detailing share repurchase or issuance activities. Comparing this content to the provided definitions, the category 'Transaction in Own Shares (Code: POS)' is the most accurate fit, as it specifically covers reports of the company buying back or selling its own shares.
2023-07-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.